Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc.
Neurocognitive functioning declines across central nervous system cancers, shaped by tumor type, location, and treatment. A ...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, /PRNewswire/ -- ...
Researchers from the Alliance for Clinical Trials in Oncology have found that two targeted immunotherapy drugs lead to high ...
A new study led by UCLA investigators found that combining zanzalintinib, a targeted therapy drug, and atezolizumab, an ...
A review of recent literature shows bioengineering is reshaping oncology, from synthetic biology to nanomedicine, but what's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results